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TARGETED CANCER THERAPEUTICS BY ADOPTIVE
TRANSFER OF MONONUCLEAR SPLENOCYTES
by
JACLYN MURTON
B.S. BIOLOGY, UNIVERSITY OF NEW MEXICO, 2005

ABSTRACT
The most common cause of cancer deaths among women is breast cancer.
Current breast cancer chemotherapies rely on passive diffusion of the drug into
the tumor interior, which leads to a sub-optimal drug concentration in some
tumor regions. One important goal for cancer pharmaceutics is optimizing drug
targeting to tumors. We propose to develop active drug delivery, mediated by the
patient’s immune cells. We hypothesize that circulating monocytes, known to
infiltrate tumors, are effective biologically-active carriers of multifunctional
nanoparticles. Peripheral blood mononuclear cells (MS) were isolated from the
spleens of transgenic mice that are immunocompetent and spontaneously
develop mammary tumors. We demonstrate that MS remain viable after being
loaded with a nanoparticle cargo (protocells). The protocell biodistribution was
assessed in vivo by radioimaging of tumor-bearing and normal mice injected with
protocell-loaded MS, and demonstrated a preferential accumulation of protocells
in tumor relative to normal mammary tissue.
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Chapter 1
Introduction

1.1 PURPOSE OF THE STUDY
The purpose of this study is to develop a method of active delivery involving
loading immune cells with therapeutic nanodrugs. We will identify and
characterize phagocytic tumor infiltrating immune cells as cargo carriers for
breast cancer treatment in a mouse model for breast cancer.

1.2 HYPOTHESIS
We hypothesize that tumor infiltrating monocytes are effective biologicallyactive carriers of multifunctional nanoparticles.

1.3 SIGNIFICANCE
Improvement of drug targeting to tumors will significantly diminish the
unpleasant side effects of chemotherapy by reducing the systemic exposure to
chemotherapeutics and the concentration required to elicit an effective tumor
dose. Immune cell carriers might also prolong the half-life of drugs that are
susceptible to environmental factors.
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Chapter 2
Review of Related Literature

2.1 CHALLENGES IN BREAST CANCER
Invasive breast cancer accounts for 23% of all cancers in women globally and
is the most common carcinoma diagnosed in women. The highest incidence of
breast cancer occur in affluent populations in Australia, Europe and North
America (Lakhani 2012). In 2012, the World Health Organization identified a
sharp rise in breast cancer worldwide. The incidence of breast cancer diagnoses
increased by 20% since 2008 and the mortality rate increased by 14%. The
most common cause of cancer related mortalities among women is through
complications with breast cancer (Terrassee 2013).
Cancers are challenging to diagnose and often require invasive therapies
such as surgery, chemotherapy, hormone therapy, and targeted therapy.
Invasive cancers require more aggressive treatment strategies that result in
uncomfortable side effects like hair loss, nausea, low blood cell counts,
neuropathy, and heart damage (Bae 2011). The physiology of breast tissue
renders it particularly susceptible to cancer. The mammary gland epithelium is
highly dynamic and undergoes dramatic changes in response to the hormonal
changes of normal female development and pregnancy (Visvader 2009). The
developmental stage of breast cells is dependent on the maturity of the woman
and whether or not she has had a full-term pregnancy. Epidemiological studies
strongly suggest that androgens, estrogens, and progesteogens play an
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important role in the development of carcinomas (Lakhani 2012). The hormone
estrogen stimulates cell division in response to the various developmental and
reproductive requirements throughout a woman's lifespan, increasing the risk of
permanent DNA damage (Nakada 2014). Immature breast cells tend to bind
more carcinogens and are less effective at repairing DNA damage compared to
mature cells. Most breast development occurs between puberty and a woman's
first pregnancy, which is why the risk of breast cancer is increased in women
who have not had a full-term pregnancy before 35 years of age (Russo 1982).
After a woman's first full-term pregnancy, the majority of immature stem cells
transform into differentiated milk producing cells, which are less sensitive to DNA
damage (Visvader 2009). Also, cancer is more likely to occur in tissues with
immature cells that are rapidly dividing, so the risk of carcinogenesis goes down
as more immature stem cells differentiate.
In addition to the susceptibility of breast tissue towards cancerization, the
physiological architecture of the breast intensifies the risk of metastasis. The
breast is an interconnected network of ducts and lobes accessible to the
lymphatic system, which allows transformed cells easy access to the rest of the
body. The risk of developing inflammatory carcinomas is also increased in
breast tissue due to the close proximity of the lymphatic network and invasive
ductal carcinomas account for roughly 80% of breast cancer diagnoses
(Siziopikou 2013).
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2.2 PATHOPHYSIOLOGY OF BREAST CANCER
Combating breast cancer requires an understanding of the pathophysiology
of the disease. Breast cancer is traditionally subdivided into four main types: two
non-invasive and two invasive cancers. The two noninvasive, or in situ, cancers
are ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). DCIS
accounts for 20% of breast cancer diagnoses and involves epithelial
transformation towards malignancy, though confined within the basement
membrane (Siziopikou 2013). The less commonly diagnosed LCIS is a
noninvasive lesion found in and confined to lobules and terminal ducts (Afonso
2008). The invasive forms of breast cancer are referred to as infiltrating ductal
and lobular carcinomas and are the second most common type of breast cancer,
accounting for up to 14% of cases (Harake 2001). In both cases, cellular
proliferation escapes the wall of the duct or lobule. The severity of the four main
types of breast cancer is categorized by four stages of development. Healthy
breast tissue ducts and lobules are subdivided into terminal ductal lobular units
that contain ducts and lobules composed of a bi-layered epithelium consisting
primarily of luminal and myoepithelial cells. In the initial stages of carcinoma
development, abnormal cell layers begin to proliferate within the duct or lobule
forming a premalignant lesion called an atypical ductal hyperplasia. These in
situ cancers are considered "Stage 0" because the transformed cells are
contained within the basement membrane of the tissue (Vargo-Gogola 2007). If
cellular proliferation exceeds two centimeters the cancer has progressed to
"Stage I". As control of proliferation, survival and differentiation becomes
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deregulated, the surrounding stroma becomes more aberrant. The proliferating
cells begin to invade the basement membrane and proliferate throughout the
surrounding tissue. Once the tumor spreads to the lymph nodes, but remains
between two and five centimeters in size it is considered "Stage II". A tumor
greater than five centimeters and spreading to the lymph nodes under the arms
is considered "Stage III". Tumor metastases are achieved once tumor cells
begin to enter the vasculature, surviving in the absence of adhesion, and can exit
the vasculature to establish a new tumor microenvironment. This is considered
the fourth and final stage of breast cancer (MD Consult 2000).

2.3 THERAPEUTIC STRATEGIES
Mammography, combined with histological sampling of core biopsies and
fine-needle aspiration cytology, is the primary imaging method for detection of
breast cancer in women over 40 years old. Invasive breast cancer is difficult to
definitively diagnose with mammography alone, so ultrasound is often used to
improve specificity. Magnetic resonance imaging is the most sensitive method
for detecting breast cancer, but is reserved for high risk cases due to the
expense (Lakhani 2012).
Therapeutic responses to breast cancer are complicated by the heterogeneity
of the disease (Lakhani 2012). There is a significant level of diversity of tumor
types both within the disease and between individuals due to the multiplicity of
neoplasms that can arise from ductal epithelial cells. Cellular diversity, as
influenced by genetic and epigenetic alterations along with adaptive responses
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to activated signaling pathways, may occur within tumors. This would explain the
diversity of breast tumor subtypes as being composed of different populations of
cancer cells. Traditional pathology driven classification has transitioned more
towards molecular based classifications to account for the heterogeneity of
cancer cell phenotypes combined with the dynamic plasticity of the tumor
microenvironment. Further complicating treatment strategies, clonal composition
and cellular phenotypes are constantly changing as the tumor environment
changes, making tumor biology more of a moving target (Polyak 2011).
The considerable range and complexity of molecular events contributing to
carcinogenesis elevates cancer to key research status among several institutions
in academia, industry, and non-profit groups. The National Cancer Institute
alone had a budget of $4.8 billion for fiscal year 2013 (Varmus 2013). Though
there are several approaches to mitigating cancer, treatment customarily focuses
on cytotoxic compounds that have a narrow therapeutic index and high doselimiting toxicity. Effective treatment often requires the dosage to approach the
maximum tolerated levels of the drug, resulting in a demanding regimen for the
patient to tolerate. Efforts toward alleviating impact on the patient have diverged
into two primary approaches, including finding ways to lower the systemic dose
while maximizing the targeted dose or finding alternatives to chemotherapeutics.
This work focuses on improving targeted delivery of chemotherapeutics.
The concept of targeting drugs to specific cell types was first developed by
Paul Ehrlich in the 1890's. Also the founder of chemotherapy, Ehrlich believed
we could learn how to "aim chemically" as a targeted approach to treating
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disease. He famously coined the phrase "magic bullet" when suggesting using
small molecules to uniquely target cancer cells (Strebhardt 2008). Ehrlich's
ideas have inspired the cancer pharmaceutics community. Several strategies
have developed towards reaching specific cancer targets. Advances in
nanotechnology and biotechnology contributed the development of engineered
nanomaterials for targeted therapies (Sanna 2014). Synthetic nucleic acid
ligands, called aptamers, show promise for targeted oligonucleotide based
therapies (Dassie 2013). Antibodies and other ligands are classic tools for
cancer treatment and immune modulation (Sliwkowski 2013). Other vehicles for
drug delivery that have emerged include microbubbles, liposomes, and micelles,
which encapsulate the drug as it passively circulates towards the intended target
(Zhou 2013).
Though significant progress has been made in drug delivery, there are still
substantial challenges to overcome concerning treating solid tumors.
Overcoming these obstacles requires an understanding of the in vivo dynamics
of intravenous (IV) drug transport. Drug targeting strategies are traditionally
divided into two approaches: active or passive targeting. Passive targeting
capitalizes on the enhanced permeability and retention (EPR) effect whereby the
leaky vasculature and poor lymphatic drainage of tumors encourages
accumulation of macromolecules or nanoparticles in the tumor interstitium.
Tumor cells stimulate angiogenesis in order to supply sufficient oxygen and
nutrients to support cellular proliferation. The imbalance of pro and antiangiogenic signaling that arises results in an abnormal vascular network of
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dilated blood vessels with disorganized branching. Though not a targeted
therapeutic approach, this strategy relies on the propensity for macromolecular
therapeutics to accumulate in the tumor interstitium more prevalently than in
normal tissue, thus facilitating a 20-30% larger effective dose in tumors
compared to normal tissue (Kobayashi 2014). However the significant
heterogeneity of tumor types with respect to vascular pore dimension and
vascular architecture limits the predictability of clinical outcomes and the
heterogeneous flood flow within a tumor prevents a homogeneous exposure of
the drug within the tumor (Prabhakar 2013; Kobayashi 2014). Though the leaky
vasculature enables macromolecules to infiltrate the tumor stroma, it also
contributes to an increase in interstitial fluid pressure, which offsets extravasation
from the blood vessel into tumors and compresses blood vessels such that blood
is diverted from the center of the tumor towards the periphery (Kobayashi 2014).
One approach to active targeting requires specific interactions between the
drug and the target cell, typically through a ligand-receptor interaction. However,
the affinity range of ligand-receptor interactions is less than 15 nm (Leckband
2000). Therefore, ligand-receptor interactions are effective for enhancing
retention after the drug enters the tumor, but the ligand-receptor affinity range is
too small to facilitate deeper penetration into the tumor from the blood vessel
entry point. This strategy might be better described as “targeted retention” rather
than “targeted delivery.” Another limitation to ligand-mediated active targeting for
cancer therapeutics is the heterogeneity of the cancer cell population. The
fraction of tumor cells expressing a specific receptor at any given time is typically
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not known, so the ligand-targeted drug is not necessarily targeting all cancer
cells within a tumor (Bae 2011).

2.4 PROTOCELLS
Advances in nanomaterials and materials science have opened the doors for
optimizing drug delivery to tumors. Nanomaterials are conveniently versatile
such that size, charge, surface coating, and composition can be modified.
Collaborative efforts towards addressing the multiple challenges to drug delivery
at the Advanced Materials Laboratory in Albuquerque, New Mexico have
successfully merged liposome technology with materials science to develop a
multicomponent lipid-bilayer-coated nanoporous particle capable of carrying
various types of cargo for cancer therapeutics. Liposomes were fused to a
spherical nanoporous silica core, forming a supported lipid bilayer that can be
used as a novel nanocarrier construct, which can be modified with targeting or
fusogenic peptides and polyethylene glycol (Ashley 2011). These nanocarriers,
called protocells, are designed to enhance the effective dose, selectivity and
stability of cancer therapeutics. The high surface area of the nanoporous silica
core increases the capacity for therapeutic agents compared to liposomes of
similar size. The lipid bilayer is supported by the silica core both structurally and
by charge, making the bilayer more stable than liposomes. Protocells are
designed to bind with high affinity to cancer cells, become internalized by
receptor-mediated endocytosis and release their cargo in the cytosol upon
endosome acidification. The cargo is then released into the cytoplasm or
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nucleus of the cancer cell, causing cell death (Ashley 2011). Protocells are
impressive tools for drug delivery that resolve the issue of protecting the drug
during transport, concentrating the effective dose, and providing a mechanism of
controlled release. However, protocells remain susceptible to the common
obstacles of other targeted therapeutics in that their targetability is limited to the
affinity range of surface ligands. Therefore, protocells still must extravasate and
passively diffuse through the tumor to reach all targets. Developing a means of
active delivery will significantly enhance the performance of protocells and other
multimodal delivery platforms.

2.5 TUMOR IMMUNOLOGY
The immune system plays two roles in cancer development and
progression. Innate and adaptive immune cells eradicate malignant cells that
are marked for destruction by cytotoxic T cells or display signs of apoptosis.
Cancer cells, on the other hand, are adept at employing the wound healing
dimension of the immune system to promote tumor growth and metastasis
(Gutkin 2014). Macrophage presence is increased in tumors compared to
healthy tissue and are a major component of leukocyte infiltration in many types
of malignant tumors (Talmadge 2007). M1 macrophages predominantly express
the killer phenotype and are largely found in tumor islets, while tissue repairing
M2 macrophages are present in tumor stroma. Not all tumor associated immune
cells are fully differentiated. Myeloid-derived suppressor cells (MDSC) are
immature immune cells that accumulate in blood, lymph nodes, bone marrow
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and tumor sites of cancer patients and are thought to play a role in suppressing
immune response (Gutkin 2014). Cancer patients typically have significantly
higher numbers of MDSCs, though the frequency of MDSC subsets differs
among cancer types. A subset of MDSCs that express neither monocytic nor
granulocytic markers has been found in the blood of patients with breast cancer,
and the frequency of MDSCs appears to correlate with tumor burden (Solito S.
2011). These mobile phagocytic and tumor associated immune cells offer a
unique opportunity for targeted drug delivery.

2.6 IMMUNE CELL MEDIATED DELIVERY OF CANCER THERAPEUTICS
Several research groups are investigating ways to engage immune cells in
the active delivery of therapeutics. Choi et al. developed a photoinduceable
therapy using gold nanoshells with peripheral blood monocytes who function as
Trojan Horses for drug delivery to solid tumors. Their idea is based on the
observation that macrophages may comprise up to seventy percent of the tumor
mass. Peripheral blood monocytes will differentiate into tumor associated
macrophages (TAM) once they cross the endothelial basement membrane (Choi
2007). Cells of the mononuclear phagocytic system are of particular interest to
liposome drug delivery groups due to their plasticity, phagocytic capacity, and
natural affinity towards migrating to tumors (Kelly 2011). For example, human
monocytes were successfully labeled with superparamagnetic iron oxide
nanoparticles to evaluate potential for magnetic resonance detection and
potential hyperthermic delivery (Engberink 2007).
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2.7 IMMUNE-COMPETENT MOUSE MODEL OF BREAST CANCER
Drug delivery research typically starts with in vitro studies to test the targeted
delivery strategy being examined and measure the concentration needed to
inhibit 50% of cellular growth. However the scope of in vitro experiments is
limited because the experimental model does not adequately reflect the clinical
scenario, making it difficult to predict therapeutic efficacy in clinical settings. In
vivo testing is more representative of the clinical disease and is usually done in
xenograft models, which are immunosupressed genetically modified mice that
are designed to allow injected human cancer cells to develop into xenograft
tumors (Bae 2011). Xenograft models are not ideal for testing immune based
cancer therapies since they do not have a functioning immune system.
Therefore, all in vivo investigations in this study were conducted in an
immunocompetent MMTV-PyMT transgenic mouse model of breast cancer that
expresses activated polyomavirus middle T antigen with a mouse mammary
tumor virus promoter (MMTV-PyMT) resulting in spontaneous mammary tumor
development by approximately 10 weeks of age.
Murine polyoma virus (PyV) causes tumor formation in a variety of cell types.
Three main PyV oncoproteins, the large (LT), middle (MT), and small tumor
antigens (ST), are known to contribute to neoplastic transformation. The middle
tumor antigen is vital for tumorigenesis after viral infection. A membrane
associated protein, MT recruits tyrosine kinases to Src family signaling molecules
for downstream regulation of viral DNA replication and RNA transcription (Fluck
2009). MT expression under the control of the MMTV promoter is restricted to
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the mammary epithelium where it induces several signaling pathways, such as
ras and phosphinositide-3-kinase (PI3K), which are commonly affected in human
breast cancer and lead to the development of metastatic carcinomas (Lin 2003).
In the current study, FVB mice were genetically modified to express the PyMT
oncoprotein in mammary epithelial cells of female mice using a mouse mammary
tumor virus long terminal repeat promoter (MMTV-LTR). The MMTV promoter is
hormonally regulated. MMTV-LTR promoters typically cause transgene
expression throughout the ductal tree of the mammary (Vargo-Gogola 2007).
Tumor development progresses from hyperplasia, as early as four weeks of age,
to adenoma/mammary intraepithelial neoplasia, carcinoma in situ, at around 10
weeks, and finally to invasive carcinoma which is correlated with the
development of pulmonary metastases at approximately 14 weeks of age (Fluck
2009).
MMTV-PYMT mice are excellent models of human breast cancer because
this model mimics four distinct stages of tumor progression from premalignant to
malignant that are comparable to tumor progression in human breast cancer. In
addition to the similar pathophysiology, PyMT tumors express similar biomarkers
found in breast tumors associated with poor outcome, such as low estrogen and
progesterone receptor expression (Lin 2003). This mouse model has contributed
insights into the mechanisms that regulate cell growth and the impact of
deregulated cell growth on the tumor microenvironment. Studies on
polyomavirus mouse models have illuminated the role of tyrosine
phosphorylation, PI3K and p53 in cellular transition to carcinogenesis (Fluck
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2009). Knockout studies of steroid receptor coactivator-1 (SRC-1), whereby
SRC-1-/- mice were backcrossed with FVB mice and cross-bred with PyMT mice,
clarify the link of SRC-1 to tumor metastasis as a loss of SRC-1 expression
suppresses breast cancer metastases in PyMT mice (Wang 2009).
The PyMT mouse model exhibits similar tumor inflammatory responses
observed in malignant breast tumors (Lin 2003). A large portion of the
leukocytes that infiltrate PyMT tumors are macrophages. Several aspects of
macrophage-epithelial cell interactions have been well characterized in PyMT
tumors. Macrophages are recruited to premalignant hyperplastic lesions in
PyMT mammary tumors by colony stimulating factor-1 (CSF-1) overexpression,
just before the angiogenic switch that leads to malignancy (Lewis 2006). These
TAMs accelerate vascularization of the lesions, which enhances tumor growth
and facilitates progression towards malignancy. During tumor formation, TAMS
tend to accumulate in hypoxic and necrotic areas, which appear to inhibit further
migration, thus immobilizing the macrophages in these regions. TAMs mitigate
to hypoxic environments by up-regulating transcription factors and other
proangiogenic factors to increase oxygen flow. The extensive involvement of
macrophages in vessel formation and remodeling in hypoxic regions of tissue
makes macrophages key modulators of angiogenesis (Lewis 2006).
Although MMTV-PyMT mice are excellent models of human breast cancer,
there are a few differences to consider. MT tumors primarily metastasize to the
lung, whereas human metastases are more broadly distributed to the brain,
lungs, bones and liver. The MMTV promoter facilitates MT expression
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throughout the ductal tree, which does not mimic oncogene expression in a more
limited number of cells in human tumors. Expression levels of the MT oncogene
are likely higher than oncogenic expression in human tumors. Also, the MMTV
promoter may not target all of the same progenitor cell types that are involved in
human breast cancer tumor formation (Fluck 2009).
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Chapter 3
Isolation and Characterization of Potential Immune Cell Carriers

3.1 INTRODUCTION
The heterogeneous cell types involved in an inflammatory response to tumor
development suggests a broad spectrum approach towards identifying potential
immune cell carriers for therapeutic delivery. Circulating immature myeloid cells
are strong candidates for drug transport because they naturally extravasate from
the bloodstream into tissue stroma to scavenge toxic compounds and remove
apoptotic cells, demonstrating phagocytic capacity (Auffray 2009). Myeloid cells
are often associated with the tumor stroma and microenvironment and can be
enriched from the patient's blood, lymph nodes and bone marrow (Gutkin 2014).
Myeloid cells comprise 53-86% of leukocytes in normal human blood and are
known to expand in breast cancer as monocytes, which function as a reservoir of
precursor innate immune cells, and are recruited to the tumor by cytokine
signaling (Auffray 2009; Danilin 2012). Monocytes are comprised of discrete
functional subsets such as MDSCs, which are typically tumor-associated and
identified in mice as mononuclear Gr1+CD11b+. MDSC proliferate in the spleen
in response to tumor progression and impair regulatory T cell activity (Auffray
2009). Therefore, we hypothesize that circulating mononuclear cells are
effective biologically active carriers of cancer nanotherapeutics. To test this
hypothesis, a mixed population of mononuclear immune cells were harvested
from the spleens of immunocompetent PyMT mice and examined for their
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potential to deliver cargo to endogenous mammary epithelial tumors and
compared to fully mature macrophages derived from bone marrow.

3.2 METHODS
3.2.1 Establishment of PyMT Mice
All procedures involving mice were conducted in accordance with the
National Institutes of Health regulations concerning the use and care of
experimental animals. This study was approved by the University of New Mexico
School of Medicine Institutional Animal Care and Use Committee.
Immune cell mediated targeted drug delivery studies require animal models
with an intact immune system. The MMTV-PyMT mouse model used in this
study is immunocompetent and spontaneously develops mammary epithelial
tumors that mimic tumor progression in human breast cancer (Fluck 2009).
FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) mice were purchased from the
Jackson Laboratory (Bar Harbor, ME) and housed in the animal research facility
at the University of New Mexico School of Medicine. The mice were maintained
at 22-23°C on a 12 hour light and dark cycle and their genomic DNA assessed
through polymerase chain reaction around 5 weeks of age to assure the PyMT
genotype. PyMT mice developed epithelial carcinomas over the course of 10-12
weeks prior to testing.
3.2.2 Extraction of Mononuclear Immune Cells from Spleen
TAM progenitor cells have been shown to continuously seed tumors by
renewing TAM subsets. These myeloid progenitor cells produce a tumor-
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monocyte pool of Ly6C high expressing circulating mononuclear cells (Movahedi
2010). Though in clinical applications these cells can be enriched from blood,
the blood volume of mice is insufficient for extracting mononuclear cells.
Therefore, circulating mononuclear cells were harvested from the spleen
reservoir of female PyMT mice by maceration of the spleen using the rubber
stopper of a 10 mL sterile syringe over a 40-micron sterile strainer connected to
a 50 mL conical vial. The strainer was rinsed with 10 mL Roswell Park Memorial
Institute Medium (RPMI-1640) media (HyClone) and the cells pelleted by
centrifugation at 400 x g for 10 min. at room temperature and resuspended in
RPMI-1640 medium for purification of mononuclear cells (Kruisbeek 2001).
3.2.3 Purification of Mononuclear Splenocytes
Mononuclear splenocytes (MS) were density gradient separated from the
spleen via flotation. Four volumes of 60% (w/v) OptiPrep (Sigma Aldrich) were
mixed with two volumes of RPMI-1640 to produce a solution of density 1.215
g/mL. Splenocytes were suspended in 3.9 mL of media and gently mixed with
2.1 mL of the 1.215 g/mL density gradient. One milliliter of media was layered
on top and the solution was centrifuged at 1500 x g for 20 min at 4°C in a
swinging bucket rotor (Fisher 1998). MS were extracted from the floating layer of
the density gradient (Figure 1 A, red arrow) and washed two times with RPMI1640 to remove residual density gradient medium. Viability post density gradient
isolation was assessed by flow cytometry using Live/Dead Violet Dead Cell Stain
Kit (Life Technologies). In summary, the cell suspension was adjusted to 1X10 6
cells/mL in 1X phosphate buffered saline (PBS). Live/Dead violet dye was
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added to the solution at a 1% concentration and incubated on ice for 30 min.
Following staining, the cells were washed several times by centrifugation at 500
x g for 10 min. and resuspended in 1X PBS. Finally, the cells were fixed in 4%
paraformaldehyde (PFA) for 15 min. and analyzed by flow cytometry.
3.2.4 Preparation of Bone Marrow Derived Macrophages (BMDM)
Bone marrow was harvested from 10 week old female PyMT mice and the
femurs and tibias extracted and placed in a dish of 70% ethanol prior to
extraction of the bone marrow. Bone marrow was flushed out of the bones onto
a 40 μm cell strainer using a 10 mL syringe with a 27 gauge needle. The bone
marrow was broken apart over the 40 μm strainer using the rubber stopper of a
10 mL syringe and rinsed with serum free Dulbecco's Modified Eagle's Medium
(DMEM) media into a 15 mL conical vial. The subsequent strained cells were
pelleted by centrifugation at 500 x g for 5 min. and resuspended in L-cell
conditioned media. The bone marrow cells were then conditioned towards M1
phenotype in culture with L-cell conditioned media for seven days at 37°C and
5% CO2. L-cell media was refreshed on the fourth and sixth day of conditioning.
Differentiated BMDM were then characterized as described below.
3.2.5 Morphological Analysis of MS and BMDM
Cell morphology was characterized in vitro by May-Grünwald-Geimsa
staining. Cells were smeared onto SuperFrost Plus microscope slides and
allowed to air dry after fixation with 4% PFA at room temperature or 100%
methanol fixation on ice for 15 min. The cells were then stained with 0.2% MayGrünwald’s eosin-methylene blue in methanol for 5 min., followed by staining
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with Geimsa working solution (73% methanol, 26% glycerol, 0.6% Geimsa’s
Azur-Eosin-Methylene Blue) for 12 min. The slides were then washed with clean
67 mM potassium dihydrogen phosphate buffer for 2, 5, and 2 min. The slides
were allowed to air dry prior to mounting with Permount. Finally, the stained cells
were imaged in a Nikon microscope at 100X with oil immersion.
3.2.6 Phenotypic Analysis of MS and BMDM
The purified MS and BMDM were surveyed for particular cell surface
expression of an adhesion G protein-coupled receptor called F4/80, which is
associated with mature M1 macrophages. The MS and BMDM populations were
also surveyed for receptors indicative of myeloid derived suppressor cells, such
as the myeloid differentiation antigen (Ly6C/G (GR1)) and integrin receptor
CD11b. Quantitative analysis regarding purity and percent viability of enriched
MS and BMDM was assessed by flow cytometry and fluorescence microscopy.
Enriched MS and BMDM were immunostained by first blocking Fc receptors with
5 ug/mL anti-mouse CD16/32 antibody (BioLegend) for 10 min. at room
temperature. The cells were then stained with 0.5 ug/mL FITC anti-mouse
CD11b or F4/80 and PE anti-mouse Ly6C/G (Gr1) antibodies (BioLegend) for 20
min. on ice and washed twice by centrifugation at 400 x g for 10 min. and
resuspended in Hanks Balanced Salt Solution (HBSS) with 0.5% horse serum
(Movahedi 2010). Finally, the cells were stained with 1% Live/Dead Violet for 30
min. on ice and washed twice as described in section 3.2.3. The cells were fixed
in 4% PFA for 15 min. at room temperature, washed twice in 1X PBS and
resuspended to a concentration of 1X106 cells/mL in 1X PBS for flow analysis

20

using a BD Fortessa four color flow cytometer. Size and granularity were gaited
on the unstained sample. Antibody specificity was confirmed with PE and FITC
isotype controls (BioLegend). Compensation of fluorochrome emission overlap
was assessed using single FITC, PE, and Violet controls.
3.2.7 Phagocytic Capacity of MS and BMDM
To establish the proportion of phagocytic MS harvested from the spleen, the
cells were labeled by phagocytosis of PKH26 dye aggregates (Sigma Aldrich).
PKH26 forms dye micro-aggregates that are resistant to metabolic attack, thus
remaining intact within cells post ingestion. Isolated monocytes were
resuspended in 1 mL of Diluent B for precipitation of PKH 26 into 100 nm
micelles and incubated with 10 μm PKH26 Red Fluorescent Cell Linker for 5 min.
at room temperature. Following the incubation, 2 mL of horse serum was added
to quench the reaction and the cells were washed twice in Dulbecco’s PBS with
0.5% horse serum or RPMI-1640 media. The cells were then fixed with 4% PFA
for 15 min. and analyzed by flow cytometry. Size and granularity were gated on
the unstained sample. Quantitation of PKH26 positive cells was calculated
proportional to 10,000 events.
M1 macrophages have a unique ability to ingest large particles that are not
identified as part of the host. To confirm this ability in the simulated M1
macrophage population, BMDM were incubated with 1 μm yellow-green
fluorescing latex beads (Sigma Aldrich) for one hour at 37°C and 5% CO 2. The
BMDM were washed several times with DMEM to remove the excess beads and
stained using May-Grünwald-Geimsa staining or Rhodamine-phalloidin staining
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of actin and 4',6-Diamidino-2-phenylindole, dilactate (DAPI) staining of the
nucleus for fluorescence microscopy.

3.3 RESULTS
3.3.1 Viability and Morphology of MS and BMDM
Figure 1 A (red arrow) shows the population of MS enriched by density
gradient separation (described in Section 3.2.3). Flow cytometric analysis of MS
viability post isolation suggests that the majority of MS survive density gradient
enrichment, though ~18% of the population showed signs of cell death (Figure
1B). In Figure 2 A, May-Grünwald-Geimsa staining of the density gradient
separated flotation layer of PyMT splenocytes shows predominantly
mononuclear morphology. The variable nuclei morphologies and cytoplasm to
nucleus ratios of the MS, shown in Figure 2 A, are typical of mixed monocyte
populations (Sliwkowski 2013). In vivo biodistribution studies (see Chapters 4
and 5) MS are compared against fully differentiated M1 macrophages to
determine if the maturity of mononuclear immune cells affected targeted delivery
to mammary epithelial tumors. Here, May-Grünwald-Geimsa staining shows that
the BMDM were significantly larger and more oblong in shape, suggesting the
population is largely composed of cells exhibiting the macrophage phenotype
(Figure 2B).
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Figure 1: Density Gradient Isolation of Mononuclear Splenoctyes (MS). The MS
cell layer after density gradient separation (A, red arrow) is captured between the top
layer of Optiprep and the bottom layer of RPMI-1640 medium after centrifugation.
Density gradient separated MS were stained with Live/Dead Violet and analyzed by flow
cytometry to confirm that the majority of the mononuclear cell population (82.2%) remain
viable post density gradient separation (B).

Figure 2: Morphology of Density Gradient Separated Mononuclear Splenocytes
(MS) and Bone Marrow-Derived Macrophages (BMDM). May-Grünwald-Geimsa
stained MS exhibited predominantly lymphocyte morphology with a prominent circular
nucleus and high nucleus-to-cytoplasm ratio (A). BMDM, cultured in L-cell conditioned
media for 7 days, are significantly larger and more spread out with a much smaller and
more uniform cytoplasm-to-nucleus ratio (B). Both images taken at 100X under oil
immersion and the scale bar measure 0.01 mm.
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3.3.2 Phenotype of MS and BMDM
TAMs are generally defined as CD11b+ F4/80+ and can adopt further
subphenotypes depending on the tumor microenvironment, such as becoming
classically activated (M1) or immunosuppressive (M2) macrophages (Chioda
2011). In order to assess whether TAMs or immature myeloid cells are more
effective tumor targeting immune cells post IV injection, density gradient purified
MS were compared against BMDM. Flow cytometry demonstrated that BMDM
exhibited higher expression levels of F4/80 (Figure 3B), whereas only a small
subset of the MS population stained positive for F4/80 (Figure 3D). BMDM were
predominantly CD11b positive (91%), whereas the MS population expressed
very low levels of CD11b and higher levels of Ly6C (~13%) (Figure 3 A&C).
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Figure 3: MS and BMDM Expression of Myeloid-like Receptors. Flow cytometry of
BMDM confirms CD11b expression with minimal Gr1 expression (A). Fluorescence
microscopy at 32X of BMDM confirms predominant F4/80 expression (green with the
nuclei counterstained blue using DAPI), which is characteristic of M1 macrophages (B).
Fluorescence microscopy (32X) of MS shows that only a small fraction express F4/80
(green with blue DAPI stained nuclei). Flow cytometry of MS demonstrates a
predominance of Ly6C expressing cells (C). The scale bars measures 0.01mm.

3.3.3 Phagocytic Capacity of MS and BMDM
Fluorescence microscopy of MS incubated with 100 nm PKH26 micelles (red)
shows a subset of MS took up PKH26 (Figure 4A, gate P2). Flow cytometric
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analysis of MS incubated with PKH26 micelles shows that the 35.5% of the MS
population identified as monocyte/macrophage lineage (by forward scatter/side
scatter) exhibit a high level of PKH26 micelle uptake (Figure 4A, gate P1) with
99% of this subpopulation identified as strongly PKH26 positive (Figure 4B, left).
By contrast the remaining MS population was 71.8% positive for PKH26 staining
(Figure 4A, gate P2), but the fluorescence intensity was more than an order of
magnitude lower than the fluorescence intensity of the monocyte/macrophage
sub-population (Figure 4B, right), suggesting the mononcyte/macrophage
subpopulation has a higher cargo loading capacity. This shift in fluorescence
intensity is consistent with the distribution of PKH26 loaded MS shown by
fluorescence microscopy (Figure 4C).
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Figure 4: MS Phagocytosis of PKH26 Cytotracker. Flow cytometric analysis of MS
uptake of 100 nm PKH26 micelles compared to unstained MS show the MS do not
autofluoresce in the PE channel, which excites PKH26 dye (red). About 35% of the MS
population exhibited forward and side scatter characteristics of monocytes and
macrophages (A, P1) and 99% of the gated monocyte/macrophage population stained
positively for PKH26 (B right). The majority of the remaining cell population (~72%) also
stained for PKH26 (A, P2) with an overall lower intensity (B left). The proportion of
PKH26 loaded MS is visualized at 20X via fluorescence microscopy (C). The nuclei are
stained with DAPI (blue) and the PKH26 micelles are shown in red (scale bar measured
0.1 mm).

M1 macrophages have a unique ability to ingest large particles that are not
identified as part of the host. Therefore, BMDM were incubated with yellowgreen fluorescent latex beads to confirm that the BMDM are phagocytic. Both
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May-Grünwald-Geimsa staining and fluorescence analysis confirm the M1
phagocytic phenotype (Figure 5).

Figure 5: BMDM phagocytosis of 1 μm latex beads. The phagocytic phenotype of
BMDM was confirmed by co-incubation with 1 μm yellow-green latex beads. The BMDM
actin cytoskeleton was stained with Rhodamine phalloidin (red) and the nucleus stained
with DAPI (blue) and imaged at 32X to help determine if the latex beads were
phagocytosed by the BMDM (A) Phagocytosis was confirmed by May-Grünwald-Geimsa
staining at 100 X, 0.01 mm scale bar (B).
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Chapter 4
In Vivo Biodistribution of MS and BMDM
4.1 INTRODUCTION
In the previous Chapter, we demonstrated isolation and characterization of
viable MS and BMDM populations and confirmed their ability to phagocytose
nano or microparticle cargo. Thus, these cell populations display many of the
necessary characteristics to be effective at transporting a drug cargo into tumors
in vivo. In order to further demonstrate that one or both of these cell populations
is suitable for drug delivery, the in vivo biodistribution of these cell populations
were assessed after adoptive transfer, a process which involves harvesting the
cells from a donor mouse, labeling the cells in vitro, and injecting the labeled
cells into a recipient mouse.

4.2 METHODS
4.2.1 SPECT/CT Imaging of MS and BMDM Biodistribution
To test the principle of immune cell mediated tumor targeting, mononuclear
splenocyte migration was tracked in vivo post IV injection and compared against
BMDM biodistribution, in both tumor (PyMT) and non-tumor bearing (FVB) mice.
MS and BMDM were prepared as described in Sections 3.2.2, 3.2.3, and 3.2.4.
The cells were then labeled by a lipid-soluble metal complex of gamma emitting
Indium-111 with tropolone for detection by SPECT/CT (Dewanjee 1981). Metal
chelation of Indium-111 to tropolone was facilitated by adding 0.36 mL of
tropolone to 0.48 mL of indium chloride and the pH adjusted to 7.0-7.5 with 0.1
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M sodium hydroxide. The indium was incubated with tropolone for 15 min. at
room temperature, after which MS or BMDM were resuspended in serum free
RPMI-1640 media and incubated with 0.9 mL of the indium-tropolone solution at
37°C for 45 min. while rocking. The cells were then pelleted by centrifugation at
200 x g for 5 min. and resuspended in 2.4 mL media and maintained at 37°C for
IV injection.
One hundred microliters of indium labeled MS were adoptively transferred
into four 10 week old female FVB and PyMT mice at a concentration of 3X106
cells/100 uL. The same volume of indium labeled BMDM were adoptively
transferred at 200,000 cells/100 uL into one 10 week old female FVB and one
10 week old female PyMT mouse, due to insufficient quantity of BMDM cultured
from bone marrow. All mice were imaged at 30 min., 5 hrs., and 24 hrs. post
injection using Single-Photon Emission Computed Tomography (SPECT) and
Computed Tomography (CT) (NanoSPECT/CT ® Small Animal In Vivo Imager,
Bioscan, Inc., Washington, D.C.). The mice were dosed intravenously via lateral
tail vein injection with approximately 500 μCi of Indium-111 and anesthetized at
30 min., 5 and 24 hrs. post injection using Isoflurane in an anesthesia induction
chamber at 3% (with 2.5% LPM oxygen) and then placed on a heated bed
(37°C) in the imaging system. A topogram was done to determine the scan range
needed for the CT and SPECT acquisitions. Topogram acquisition parameters
consisted of 65 kVp tube voltage, 500 ms exposure time, and all mice were
prone in a feet first position. Once the scan range was determined, the 3 min.
CT acquisition was completed using 180 projections with a pitch of 1.5. Helical
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SPECT options included 32 projections and varying time per projection for
estimated acquisition times of about 24 min. Mice remained anesthetized at 2%
isoflurane (with 2.5% LPM Oxygen) during the entire imaging process and were
sacrificed post imaging.
4.2.2 Quantitative Analysis of SPECT/CT Image Data
The helical SPECT/CT images were reconstructed and regions of interest
(ROIs) selected for quantitative analysis of MS biodistribution using VivoQuant
1.22 software (inviCRO, LLC). For both PyMT and FVB mice, ROIs of central
axial sections were selected within mammary tumors or normal mammary glands
(ROIs within right mammary and left mammary at level 1, and a single ROI
covering both right and left mammary tissue at level 5); central axial sections of
liver, left kidney, and spleen were also selected. The mean and standard
deviation of the Indium-111 SPECT signal were computed for all ROIs and the
data were plotted and analyzed using Prism statistical software. Mammary
signal was plotted as a function of incubation time and the data were fit using
linear regression, where the significance of the difference in slope and elevation
were assessed.
4.2.3 Activation of MS versus Incubation Time at 37°C
MS were prepared as described in Section 3.2.2 and 3.2.3 and then treated
to mimic the injectate sample conditions from the previously described SPECT
study in Section 4.2.1. Specifically, MS were incubated in RPMI at 37°C for 30
min, 2 hrs., and 4 hrs. in a sealed container (without CO2 buffering). Activation
was assessed using a mouse monocyte cytokine array panel (R&D systems).

31

Briefly, cell culture supernatant was exposed to nitrocellulose membranes,
previously blocked with serum, spotted with GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL6, IL-10, IL-13, MCSF, and TNFα antibodies overnight. The membranes were
then washed in buffer several times before incubation with biotinylated IR Dye
800 CW for 1 hr. The membranes were again washed several times with buffer
and the fluorescently labeled captured antibodies imaged on a LiCor scanner.
The total fluorescence was background corrected and calculated by multiplying
the mean fluorescence of background to the area of the selected region of
interest, which was then subtracted from the integrated density calculated in
ImageJ (National Institutes of Health). As a positive control, RAW 264.7
immortalized murine macrophages were stimulated with 100 nM
lipopolysaccharide from E. coli for 1 hr at 37°C to induce cytokine expression.
4.2.4 Effect of Incubation at 37°C on MS Phenotype and Phagocytosis
MS were prepared as described in Section 3.2.2 and 3.2.3 and treated to
mimic the injectate sample conditions from the previous SPECT study. The MS
were incubated at 37°C for 30 min., 2 hrs., and 4 hrs. in a sealed microfuge tube
(without CO2 buffering) prior to immunological staining and labeling by PKH26
micelle phagocytosis (described in Section 3.2.7). MS were immunostained with
0.5 ug/mL FITC anti-mouse CD11b or F4/80, Brilliant Violet anti-mouse CD11c
and PE anti-mouse Ly6C/G (Gr1) antibodies as described in Section 3.2.6. The
cells were fixed in 4% PFA for 15 min. at room temperature, washed twice in 1X
PBS and resuspended to a concentration of 1X10 6 cells/mL in 1X PBS for flow
analysis using a BD Fortessa four color flow cytometer. Size and granularity

32

were gated on the unstained sample. Antibody specificity was confirmed with
Brilliant Violet, PE and FITC istotype controls (BioLegend). Compensation of
fluorochrome emission overlap was assessed using single FITC, PE, and Violet
controls.
4.2.5 Demonstrating Tumor Infiltration of Cargo-Loaded MS
To obtain visual confirmation of MS biodistribution in tumor bearing PyMT
mice, and to investigate distribution at longer time points, 2x106 PKH26 loaded
MS were adoptively transferred into eight 10-12 week old PyMT mice and
allowed to circulate for 5 hrs., 24 hrs., 48 hrs., or 72 hrs. (N=2 per time point).
Each mouse was sacrificed at the appropriate time point, and the tumors were
cryopreserved by immersion in Optimal Cutting Temperature (OCT) (VWR)
followed by snap freezing in liquid nitrogen. The tumors were then sectioned into
5 μm slices onto SuperFrost Plus microscope slides using a freezing microtome
and fixed in 4% PFA for 15 min. at room temperature. The sections were then
stained with Hematoxylin and eosin, mounted in Permount (Fisher) and imaged
on a Nikon microscope at 20 and 100X. A subset of both in vitro and in vivo
sections were also stained with 5 ug/mL wheat germ agglutinin (Invitrogen) for 10
min. at room temperature, washed twice with 1X PBS and mounted in
Vectashield with DAPI for fluorescence image analysis and a Zeiss M200
microscope at 20X and 32X.
4.2.6 Purification of Myeloid-Derived Stem Cells from MS
The Ly6C(Gr1)/CD11b double-positive cells were enriched using mouse
monocyte enrichment kits (StemCell). MS were incubated in EasySep selection
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cocktail for 15 min prior to incubation with selective magnetic nanoparticles for
10 min. CD11b+ cells were enriched by negative selection and Ly6C+ cells were
positively selected by magnetic separation using two StemCell enrichment kits.

4.3 RESULTS
4.3.1 SPECT/CT Imaging of MS and BMDM Biodistribution
Qualitatively, the SPECT/CT images of radiolabeled MS suggest a patterned
migration that changes over the course of 24 hrs. Within 30 min. post-adoptive
transfer, the majority of the radiolabeled MS were detected on tomographic
images within the liver, spleen, and kidneys of both PyMT and FVB mice, with
some signal in the heart and chest area (Figure 6, green arrow). By 5 hrs., in
both PyMT and FVB mice, the majority of the MS had migrated to the liver,
kidneys and spleen (Figure 7). The biodistribution of MS in PyMT versus FVB
diverged after 5 hrs. In half of the PyMT cohort, MS were visible in the
mammary epithelial tumors of PyMT mice, relative to the surrounding tissue,
while, visually, no signal was observed in the normal mammary glands of
corresponding FVB mice (Figure 7, red arrows). MS migration to tumors
appeared to be more prevalent in larger tumors. There was consistent signal in
the joints (e.g. knees and shoulders) of FVB mice that did not correspond in
PyMT mice (Figure 7, green arrow). By 24 hrs., MS delivery to mammary
epithelial tumors further increased in PyMT mice, while no signal was visually
apparent in the mammary glands of FVB mice, even after 24 hrs. However, MS
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presence appeared to further increase in the joints of FVB mice after 24 hrs.
circulation (Figure 8).

Figure 6: Biodistribution of Radiolabeled MS in PyMT and FVB Mice after 30 min.
Circulation. SPECT/CT was used to follow the migration of Indium-111 labeled MS,
post adoptive transfer, in PyMT (tumor bearing) and FVB (non-tumor bearing) mice at 3
time points over 24 hrs. At 30 min., SPECT images suggest the majority of adoptively
transferred MS migrate to the chest (green arrow), liver (yellow arrow), spleen (blue
arrow), and kidneys (white arrow) of PyMT and FVB mice.
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Figure 7: Biodistribution of Radiolabeled MS in PyMT and FVB Mice after 5 hrs.
Circulation. SPECT/CT was used to follow the migration of Indium-111 labeled MS,
post adoptive transfer, in PyMT (tumor bearing) and FVB (non-tumor bearing) mice at 3
time points over 24 hrs. After 5 hrs. circulation post adoptive transfer, the MS have
migrated out of the chest area and begin to appear in tumors (red arrows), though not in
the mammary glands of FVB mice (red arrows). There is also some migration to the
joints (green arrow) in FVB mice after 5 hrs.
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Figure 8: Biodistribution of Radiolabeled MS in PyMT and FVB Mice after 24 hrs.
Circulation. SPECT/CT was used to follow the migration of Indium-111 labeled MS,
post adoptive transfer, in PyMT (tumor bearing) and FVB (non-tumor bearing) mice at 3
time points over 24 hrs. SPECT images suggest the MS tumor signal is increased after
24 hrs. circulation post adoptive transfer (red arrows), though not in the mammary
glands of FVB mice (red arrows).

Quantitative analysis of three PyMT and three FVB mice injected on the
same day reveals an interesting time dependence of the mammary signal on the
injection time (Figure 9A). The MS injectate was radiolabeled at the same time,
but the injections of the six animals were carried out over the course of the day,
such that the pairs of mice (one PyMT and one FVB) were injected at
approximately 30 min., 2, and 4 hrs. after radiolabeling. The average mammary
ROI signals at 24 hrs. post-injection demonstrated a marked increase that is
linear in the delay between radiolabeling and injection (Figure 9A). The slopes of
the two lines (PyMT and FVB) are significantly different (p = 0.005) with a much
greater increase in mammary uptake versus incubation time (i.e. greater slope)
observed for the tumor-bearing cohort. The affinity of radiolabeled MS for
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tumors versus normal mammary tissue was 3.5-fold greater regardless of the
incubation time of the sample prior to injection (Figure 9B). Average tumor-toorgan ratios for PyMT and FVB mice are plotted in Figure 9C. The tumor-toliver, tumor-to-kidney and tumor-to-spleen ratios were greater in PyMT mice
relative to FVB, although the result was not statistically significant (Figure 9C).

Figure 9: Region of Interest (ROI) Analysis of SPECT/CT images of MS
biodistribution. ROIs of central axial sections were selected for tumors and mammary
glands in regions one and five and compared to ROIs of the liver, left kidney, and spleen
in PyMT and FVB mice. The mean and standard deviation of the Indium-111 SPECT
signal was calculated for all tissues using reconstructed helical SPECT images. The
quantified mammary ROI signal suggests a marked increase in tumor association after
24 hrs. that is dependent on the initial sample conditions pre-injection (A). The affinity
of MS for tumors over mammary tissue was 3.5-fold greater regardless of the incubation
time of the sample prior to injection (B). Tumor-to-organ ratios suggest a trend toward a
higher level of uptake by tumor tissue (relative to the liver, left kidney, and spleen)
compared to normal mammary tissue (C).
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Qualitatively, the biodistribution of radiolabeled BMDM was noticeably
different from the biodistribution of MS, as shown in Figure 8. Tomographic
images of radiolabeled BMDM post adoptive transfer showed localization
primarily in the lungs after 30 min. of circulation (Figure 10 red arrow). After 5
hrs. circulation, the BMDM had begun to migrate out of the lungs into the liver,
kidneys and spleen (Figure 10, white, blue, and yellow arrows). By 24 hrs., the
lungs had cleared, and the BMDM localized primarily to the liver and spleen and
to some extent the kidneys (Figure 10).

39

Figure 10: Biodistribution of Radiolabeled BMDM. SPECT/CT imaging was used to
track Indium-111 labeled BMDM migration post adoptive transfer in PyMT and FVB
mice. SPECT images suggest BMDM primarily migrate to the lungs (pink arrow). Over
the course of 24 hrs., the BMDM migrate out of the lungs and into the liver (white arrow),
kidneys (yellow arrow) and spleen (blue arrow), but not tumor (red arrows).

4.3.2 Activation of MS versus Incubation Time at 37oC
ROI analysis of SPECT/CT images of MS biodistribution suggest a positive
impact of sample incubation time at 37°C prior to injection on the biodistribution
of the injectate. The immature nature of the MS makes them particularly
susceptible to influence by external stimuli. Therefore, the conditions of the MS
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samples used in the SPECT experiment were simulated by harvesting and
labeling MS and allowing them to incubated for 30 min., 2 hr, or 4 hr to mimic the
conditions the MS experienced prior to injection during the course of the SPECT
imaging experiment. Supernatants from three MS samples were collected post
purification and PKH26 loading to establish the activation state of the cells after
each of three incubation intervals (Figure 11A). RAW 264.7 immortalized
macrophages were stimulated with 100 nM lipopolysaccharide from E. coli to
induce cytokine expression (Figure 11B). The cytokine assay showed only the
positive controls excited and, therefore, the MS demonstrated no measureable
cytokine expression over the course of up to four hrs. incubation at 37°C without
CO2, (Figure 11A).
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Figure 11: Cytokine array of Pre-injected MS. Density gradient enriched MS were
suspended in serum free RPMI-1640 medium for 30 min., 2 hrs., and 4 hrs. at 37°C in
sealed vials (without CO2) to mimic the sample conditions of the MS biodistribution
study by SPECT/CT. Cytokine array analysis of the RPMI-1640 supernatants collected
after incubation suggest no detectable level of cytokine expression as a function of time
incubated at 37°C (A). Immortalized RAW 264.7 mouse macrophages were stimulated
with 100 nM LPS to provide a positive control (B).

4.3.3 Effect of Incubation at 37°C on MS Phenotype and Phagocytosis
To further assess the apparent change in Indium-111 labeled MS injectate as
a function of incubation time, flow cytometric analysis was performed to quantify
potential changes in cell surface expression and the phagocytic capacity of the
MS injectate as a function of time incubated at 37°C. However, flow cytometric
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analysis showed no appreciable change in cell surface expression of receptors
(Figure 12 A&B), although there was a slight increase in PKH26 uptake after 4
hrs (Figure 12C). Shifts in cell size (forward scatter) and granularity (side
scatter) suggest a slight divergence of the lymphocyte and monocyte populations
and an appearance of a small yet highly granular population after 4 hrs.
incubation (Figure 13).

Figure 12: MS Biodistribution Sample Condition Analysis. MS were incubated at
37°C for 30 min., 2 hrs., and 4 hrs. and immunostained with F4/80, CD11b, Ly6C, and
CD11c antibodies to elucidate the shift in population dynamics that improved MS
biodistribution in vivo. There was no appreciable change in CD11b-Ly6c expression (A)
and only a slight change in F4/80-CD11c expression (B). PKH 26 uptake did slightly
increase after 4 hrs (C).
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Figure 13: MS Biodistribution Sample Condition Analysis. MS were incubated at
37°C for 30 min., 2 hrs., and 4 hrs. Cell size and granularity were assessed by flow
cytometry, which suggests a divergence of the lymphocyte and monocyte populations
and an appearance of a small yet highly granular population after 4 hrs. incubation.

4.3.4 Confirmation that Cargo-loaded MS Infiltrate Tumors
In the SPECT study described in Section 4.3.1, the membranes of MS and
BMDM were radiolabeled and the cells were not loaded with cargo. To
demonstrate that cargo-loaded MS are capable of infiltrating tumors in PyMT
mice, and to investigate biodistribution qualitatively at longer time points, 100 nm
PKH26-micelle loaded MS were adoptively transferred into PyMT mice and
allowed to circulate for 5 hrs., 24 hrs., 48 hrs., or 72 hrs. (N=2 per time point).
Representative tumor sections shown in Figure 14 suggest PKH26 dye (red) is
localized to branched structures within the tumors that do not appear to stain for
DAPI (blue, nuclear stain) (Figure 14 B&C). However, these structures stain
strongly with WGA (green), a lectin that stains N-acetyl-D-glucosamine and sialic
acid , suggesting a possible extracellular matrix-rich region (Ohno 1986). The
micelles are somewhat confined to the WGA-positive structures (Figure14 F-H).
There appears to be a higher quantity of PKH26 micelle localization within the
branched structures of the tumor after 5 hrs., which potentially increase over time
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(Figure 14 A-D). However, it is difficult to comprehensively assess and directly
quantify the PKH26 micelle delivery as a function of time by this method.

Figure 14: Biodistribution of PKH26 Loaded MS. Fluorescence images of 5 μm
cryosections of a tumor in mammary gland 2/3 were taken at 20X and 32X. The
extracellular matrix components were stained with Wheat Germ Agglutinin (green) to
elucidate more structure. The nuclei are stained with DAPI (blue). PKH26 fluorescence
(red) is observed in the Rhodamine channel (E-H). Images A, D, E, H and I-L were
taken at 20X, while images B, C, F, and G were taken at 32X. All scale bars measure
0.1 mm. The corresponding 5 μm slices of tissue from the similar regions as the
fluorescence images were stained with H&E (I-L), though not imaged in the exact same
area of the section.

4.3.5 Purification of Myeloid-Derived Stem Cells (MDSC) from MS
In order to determine whether Ly6C(Gr1)/CD11b double-positive MDSC were
the subset of the MS population that infiltrated the tumors, we attempted to
isolate Ly6C(Gr1)/CD11b double-positive cells, with the intent of using a highly
enriched MDSC population in future biodistribution studies. As shown in Figure

45

15, we demonstrated enrichment of CD11b MS by negative selection and further
enrichment of Ly6C(Gr1) positive cells through a positive selection kit, however,
the low yield rendered this method impractical for MDSC isolation of sufficient
cell quantities required for large in vivo biodistribution studies.

Figure15: Purification of MDSC from the MS population. MS were enriched for cells
exhibiting the MDSC phenotype (CD11b+Ly6C+) using a StemCell Negative Selection
Kit for CD11b (B) and positive selection kit for Ly6C (C). Although there is significant
enrichment of CD11b and Ly6C cells (B&C), there is an appreciable loss of the total
number of cells (B in red).
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Chapter 5
Characterization and Biodistribution of Protocell-Loaded MS
5.1 INTRODUCTION
Mononuclear phagocytes are currently attractive carrier cells for
nanotherapeutics due to their prominent involvement in innate immunity and their
capacity to engulf and respond to nanoparticles. As described in the previous
chapter, the MS examined in this study demonstrate specific tumor targeting
relative to normal mammary tissue, along with the capacity to transport
nanoparticles (PKH26 micelles), post-adoptive transfer. Modern cancer
therapies are increasingly combining nanotechnology and biotechnology to
develop more sophisticated drug formulations and drug release strategies that
add to the complexity and behavior of a potential drug cargo. Therefore, it is
important to test the compatibility and efficiency of MS-mediated (active)
nanoparticle delivery using a more complex cargo. Towards this end, we
collaborated with Dr. Eric Carnes and Dr. Carlee Ashley of Sandia National Labs
to incorporate protocells, a multi-functional nanoparticle technology, into MSmediated drug delivery.

5.2 METHODS
5.2.1 Protocell Formulation
Protocells were prepared by liposome fusion to nanoporous spherical silica
as described previously (Carroll 2009). Nanoparticle protocells had an overall
hydrodynamic diameter of 20-400 nm (180 nm average), which is considered
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within the optimal size range to deliver an adequate dose of drugs if distributed
homogeneously, such as by IV injection (Ashley 2011; Ashley 2012; Kobayashi
2014). To track the protocells in vivo, and to simulate drug encapsulation by the
protocells, the nanoporous protocell cores were amine terminated as described
previously (Ashley 2011), then reacted with 1 mg DyLight 633 or 650 in ethanol
for 8 hrs. at room temperature and washed 3 times in 2X volume of excess 200
proof ethanol prior to liposome fusion.
Initially three liposome formulations were tested in order to optimize MS
uptake while avoiding cytotoxicity and MS activation. The various formulations of
liposomes were created using previously described methods and fused to the
silica nanoparticle cores (Ashley 2011). A synthetic phosphocholine known as
1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) was used as the base lipid,
because it commonly forms liposomes in aqueous media alone or in combination
with other lipids.


DOPC-PEG Protocells. The first liposome formulation
fused to Dylight 633/650 loaded silica spheres was a mixture of DOPC,
polyethylene glycol (PEG), and cholesterol at a ratio of 6:1:3, which after
fusing to the silica nanoparticle cores results in net neutral surface
charged protocells that have a zeta potential of -10 mV in buffer that is
near neutral. Previous results have demonstrated IV circulation of DOPCPEG protocells are typically long-circulating and the PEG functions to
shield the particles from MS (Kelly 2011).
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DOPC-DOTAP Protocells. The second liposome
formulation consisted of a 3:1 ratio of DOPC and N-(1-(2,3dioleoyloxy)propyl)-N,N,N-trimethylammonium methylsulfate (DOTAP),
which is a common liposome transfection agent. The net surface charge
of this particle is anionic (-25 mV) which should facilitate rapid nonspecific uptake into all cell types along with considerable cytotoxicity.



DOPC-DOPS Protocells. The final liposome formulation
was composed of a 1:1 ratio of DOPC and 1,2-Dioleoyl-sn-glycero-3phosphoserine (DOPS). The DOPC:DOPS particles are positively
charged (+25 mV) and employ phosphatidylserines, which are known to
be preferentially taken up by macrophages (Kelly 2011).

5.2.2 MS Protocell Uptake and Cytotoxicity Analysis
The concentration of protocells incubated with MS was titrated to optimize
protocell uptake while minimizing cytotoxicity to the carrier MS. MS were
aliquotted into microfuge tubes at a concentration of 1X10 6 cells/mL and mixed
with 0.5, 1, 50, 125, 250, 500, 1000 ug/mL of protocell (DOPC-PEG, DOPCDOPS, or DOPC-DOTAP) in RPMI-1640 media with 1% horse serum and
incubated at 37°C and 5% CO2 for 20 min., 1 hr and 2 hrs. The cells were then
washed by centrifugation at 500 x g for 10 min. and resuspended in serum free
media. Viability was assessed by flow cytometry using Live/Dead Violet Dead
Cell Stain Kit as described in section 3.2.3. Flow cytometric analysis of the
live/dead stained protocells loaded with DyLight 633 and incorporated into MS
was gated on live stained and dead stained cells such that the percent protocell
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uptake is the proportion of live cells detected that are co-labeled with DyLight
633. All events detected were normalized to 10,000 for comparison between
samples.
5.2.3 In vivo Comparison of Protocell Loaded MS Biodistribution by
Protocell formulation
Density gradient isolated MS were co-incubated at a concentration of 1x106
cells/0.1 mL with 125 ug/mL protocells of each protocell formulation (PEG,
DOTAP, or DOPS) for 1 hr at 37°C and 5% CO2. Following incubation, the free
protocells were removed from the cell suspension by centrifugation at 500 x g for
10 min. and resuspended in 10 mL 1X PBS. Each category of injectate,
pertaining to the particular formulation of protocell cargo, was IV injected into one
FVB and two PyMT mice, all 10 weeks old, and circulated in vivo for 24 hrs. For
comparison, 100 uL of 125 ug/mL protocells were directly injected into 10 week
old FVB and PyMT mice and circulated in vivo for 24 hrs. The animals were
sacrificed after 24 hrs., and the left and right lobes of the liver, the spleen, the
kidneys, and all mammary glands or tumors were harvested and divided in half.
One half of each harvested tissue was digested in 62.5 U/mL Hylauronidase,
3 mg/mL Collagenase, and 0.2 μm /mL DNAse1 for 3 hrs. at 37°C on a rocker.
The digested samples were passed over a 100 μm sterile sieve and washed
twice by centrifugation at 500 x g for 10 min. and resuspended in 10 mL RPMI1640 media. The digested tissue was immediately fixed in 4% PFA for 15 min.
at room temperature and washed once in 1X PBS, and subsequently analyzed
by flow cytometry.
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The second halves of the harvested tissues were fixed whole overnight in 4%
PFA and subsequently infused with sucrose prior to immersing in OCT. The
OCT embedded tissue was then frozen in isopentane immersed in liquid nitrogen
and stored at -80°C for cryosectioning.
5.2.4 SPECT/CT Imaging of DOPC-DOPS Protocell Biodistribution after
Direct Injection, MS Adoptive Transfer, and BMDM Adoptive Transfer
Diethylenetriaminepentaacetic acid (DTPA) was amine cross-linked to 50-200
nm nanoporous silica spheres to facilitate DTPA chelation of gamma emitting
Indium-111 into protocells for detection by SPECT/CT. The indium was
incubated with the DTPA treated nanoporous silica spheres for 30 min. at room
temperature in 50 mM Sodium Citrate Buffer. Unbound Indium-111 was
removed by centrifugation at 5,000 x g for 4 min. and resuspension in 1 mL of
0.5X PBS. The wash step was repeated one time and the solution spiked with
100 uL of nanoporous silica cores infused with Dylight 650 and the final volume
raised to 1.1 mL. An equal volume of DOPC-DOPS liposomes were added to
the cores and incubated overnight at 4°C. Prior to loading into MS and BMDM,
the excess lipid was removed from the solution by centrifugation at 5,000 x g for
4 min. and resuspension in 1 mL of 1 X 106 cells/0.1 mL of either MS or BMDM
in serum free RPMI-1640 media buffered with 20 mM Hank's Balanced Salt
Solution (HBSS). The cells were incubated with Indium-111-labeled DOPCDOPS protocells for 1 hr at 37°C to facilitate protocell uptake and subsequently
washed in RPMI-1640 media as described in Section 5.2.2. The cells were
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resuspended in 1 mL serum free RPMI-1640 media buffered with 20 mM HBSS
and stored on ice prior to injection.
Protocell-loaded MS were adoptively transferred into four 12 week old female
FVB mice and four 12 week old PyMT mice at a concentration of 1 X 10 6
cells/100 uL. Protocell loaded BMDM were adoptively transferred into four 12
week old female FVB mice. An additional four 12 week old female FVB mice
and four 12 week old PyMT mice were directly injected with 630 ug of
radiolabeled protocells mixed with 350 ug of fluorescent DOPC-DOPS protocells,
at a concentration of 10 mg/mL, via IV injection. All mice were imaged by
SPECT/CT at 30 min., 5 hrs., and 24 hrs. post injection as described in section
4.2.1. Each animal was sacrificed immediately following the 24 hr imaging time
point.
Quantitative analysis of the SPECT/CT images was performed by INVICRO
(Boston, MA). ROIs were selected from SPECT/CT images, using volumes
corresponding to tumors or normal mammary glands, liver, kidneys, spleen,
brain, bone, lungs and heart of all PyMT and FVB mice in the study. The cohorts
(BMDM mediated, MS-mediated, and directly injected; PyMT and FVB) were
compared against each other, and the mean and standard deviation of the
Indium-111 SPECT signal (uptake), expressed as the percentage of the injected
dose per gram of tissue (%ID/g), was calculated for all ROIs.
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5.3 RESULTS
5.3.1 Optimization of MS Protocell Uptake and Viability
Flow cytometric analysis of MS incubated with various concentrations of three
protocell formulations suggests that 1-2 hrs. is required to optimize the
proportion of MS that take up protocells for all three protocell formulations
(Tables 1-3 in appendix). Viability remains relatively high at 1 hour incubation for
all three formulations using a protocell concentration of 125 ug/mL. Although
uptake significantly increases with increasing concentration for DOPC-PEG
protocells, the viability dramatically drops for concentrations over 250 ug/mL
(Figure 16A). The maximum percentage of MS taking up DOPC-DOTAP
particles at 1000 ug/mL was significantly higher than for DOPC-PEG particles,
but with a more substantial decrease in viability (Figure 16B). DOPC-DOPS
particles had the best overall performance with respect to uptake by MS,
combining high uptake (80%) with viability superior to that observed in DOPCDOTAP for the same incubation conditions (85% vs. 50%) (Figure 16C).
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Figure 16: Fraction and Viability of MS Loaded with Protocells. Flow cytometric
analysis of cell viability (detected by Live/Dead violet staining) and proportion of MS with
protocells after 1 hr incubation at 37°C under 5% CO2. Viability and protocell labeling
are optimized at 125 ug/mL in all three protocell formulations. DOPC-PEG protocells
were somewhat cytotoxic (~60% viability at low concentrations) and less effectively
taken up by MS compared to other protocell formulations (A). Uptake efficiency in
DOPC-DOTAP particles was optimal, though these particles are significantly cytotoxic
(B). DOPC-DOPS protocells are the most compatible with MS without compromising
cell uptake efficiency (C).
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5.3.2 Biodistribution of Different Protocell Formulations after Direct
Injection versus MS Adoptive Transfer
The biodistributions of the DOPC-DOPS, DOPC-DOTAP, and DOPC-PEG
protocells, loaded into MS, were compared in vivo in order to investigate whether
the protocell formulation influences MS migration post adoptive transfer. Flow
cytometric analysis of the digested organs suggests that there is a difference in
biodistribution of MS that is dependent on the formulation of protocell ingested.
The tumor-to-organ ratio of protocell-positive cells in tumors relative to liver,
kidney or spleen are plotted in Figure 17. MS did not significantly improve
DOPC-PEG tumor delivery (Figure 17A). However, tumor-to-liver and tumor-tospleen ratios of DOPC-DOPS protocells were enhanced by MS-mediated
delivery relative to direct injection (Figure 17B). MS-mediated delivery also
appears to improve DOPC-DOTAP protocell delivery to the tumors, relative to
direct injection (Figure 17C). These data were helpful in designing the final
SPECT imaging experiment, but the group size was too small (N=2 for PyMT
and N=1 for FVB) for statistical significance to be evaluated. Cryosections of the
second half of the tumors confirm an association of both MS-mediated and
directly injected protocells (Figure 18). As in the MS-mediated delivery of PKH26
(discussed in section 4.3.4), the protocells appear to accumulate in branched
regions of the tissue with low nuclear staining (Figure 18). The DOPC-DOPS
protocells have some association with DAPI staining in these low DAPI branched
regions (Figure 18 B&H) to a greater extent than was seen with DOPC-DOTAP
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(Figure 18 C&I) or DOPC-PEG (Figure 18 A&G). The low nuclear staining
branched regions were confirmed by H&E staining (Figure 18 D-F and J-L).

Figure 17: Biodistribution of Protocell Loaded MS. MS were loaded with different
formulations of protocells (DOPC-PEG, DOPC-DOTAP and DOPC-DOPS) and
adoptively transferred into PyMT mice. The MS were circulated in vivo for 24 hrs. prior
to digestion of the organs, followed by flow cytometric analysis of the proportion of
DyLight 650 labeled protocells in the tumors, liver, kidneys and spleen. The ratio of
signal in tumors relative to liver, kidney and spleen are shown. MS did not significantly
improve DOPC-PEG tumor delivery (A). Tumor association of DOPC-DOPS protocells
was enhanced compared to liver and spleen by MS-mediated delivery (B). MS also
improved DOPC-DOTAP particle delivery to the tumors (C).
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Figure 18: Visual Confirmation of Protocell Delivery to tumors. Five micron
cryosections from the second and third right mammary tumors after IV injection of either
MS loaded or directly injected DOPC-DOPS protocells. The cryosections were prepared
from the same tumors analyzed in Figure 17 after 24 hrs. circulation in vivo. The
protocells were imaged in the Rhodamine channel at 20X (red) and the tissue was
stained with DAPI to illuminate the nuclei (blue) (A-C and G-H). The corresponding
sections were stained with H&E and confirm low nuclear staining of the protocell
associated branched regions of tissue (D-F and J-L). Protocell delivery 500 μm into the
tumors is visually confirmed (A-C and G-I) and mimics the MS-mediated biodistribution
of PKH26 shown in Figure 14. All scale bars measure 0.1 mm.

5.3.3 SPECT/CT Imaging of DOPC-DOPS Protocell Biodistribution after
Direct Injection, MS Adoptive Transfer, and BMDM Adoptive Transfer
To more thoroughly test the efficiency of immune cell mediated drug delivery
to mammary epithelial tumors, the biodistribution of radiolabeled protocells was
imaged in vivo by SPECT/CT imaging. Specifically, the biodistribution of
protocells delivered by direct IV injection was compared to delivery by MS
adoptive transfer, in tumor (PyMT) and non-tumor (FVB) mice. Additionally,
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protocell delivery by BMDM adoptive transfer was imaged in non-tumor bearing
(FVB) mice.
SPECT/CT images demonstrate that MS-mediated DOPC-DOPS protocell
distribution is primarily localized to the liver, kidneys and spleen of both PyMT
and FVB mice (Figure 19). The average uptake of protocells by the normal
mammary tissue of FVB mice (1 %ID/g) is significantly lower (p <0.001) than the
average protocell uptake observed in the mammary tumors of PyMT mice (2
%ID/g) after 24 hrs. circulation (Figure 23). One PyMT mouse was not properly
injected and most of the sample was administered into the tail tissue, which
perhaps fortuitously resulted in a more specific association with tumors (Figure
20).
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Figure 19: Biodistribution of MS Loaded with DOPC-DOPS Protocells. MS were
co-incubated with DOPC-DOPS protocells labeled with Indium-111 and Dylight 650 and
adoptively transferred into PyMT and FVB mice. SPECT/CT images suggest that
protocell distribution is localized to the liver (white arrow), kidneys (yellow arrow) and
spleen (blue arrow) of both PyMT and FVB mice. The protocells do not visibly
accumulate in the normal mammary tissue of FVB mice (top), but do accumulate in the
tumors of PyMT mice (red arrows) over 24 hrs. circulation.
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Figure 20: Quantitative Confirmation of MS-mediated DOPC-DOPS Protocell
Biodistribution. Post SPECT/CT quantitative analysis of MS-mediated protocell
distribution was assessed by quantifying the injected dose of DOPC-DOPS protocells in
mammary/tumors, liver, kidneys and spleen using a gamma counter. The average
injected dose was normalized to muscle. One PyMT mouse was not injected properly
(image shown on right, blue arrow), but resulted in a more specific association with
tumors (left).

Qualitatively, directly injected DOPC-DOPS protocells mimic the
biodistribution of MS-mediated protocell distribution, in that protocell distribution
is again primarily localized to the liver, kidneys and spleen within 30 min. and
remains in these organs over 24 hrs (Figure 21). As observed in the case of MS
adoptive transfer, the uptake of directly-injected protocells by normal mammary
tissue of FVB mice (1 %ID/g average) is significantly lower (p < 0.0056) than the
uptake by mammary tumors in PyMT mice (2-2.5 %ID/g average) over 5 and 24
hrs. circulation (Figure 23).
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Figure 21: Biodistribution of Directly Injected DOPC-DOPS Protocells. DOPCDOPS protocells labeled with Indium-111 and Dylight 650 were injected into PyMT and
FVB mice. SPECT/CT images suggest that protocell distribution is localized to the liver
(white arrow), kidneys (yellow arrow) and spleen (blue arrow) within 30 min. and remains
in these organs over 24 hrs. The protocells do not accumulate in the normal mammary
tissue of FVB mice, but do accumulate in PyMT tumors after 24 hrs. (red arrows).
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BMDM mediated protocell biodistribution is significantly different from that
observed after MS adoptive transfer. SPECT/CT images show that protocellloaded BMDMs rapidly localize to the lungs, within 30 min. of injection (Figure
22).

Protocell-loaded BMDMs then migrate to the liver, kidneys, and spleen

over 24 hrs. The circulation time-dependence of the biodistribution of BMDM
was significant for all cohorts (p < 0.0001). In FVB mice (normal mammary
tissue), the uptake of protocell loaded BMDMs by mammary tissue is significantly
lower compared to the uptake of protocells delivered by direct injection or MS
adoptive transfer with p <0.01 at 30 min. and 5 hrs. and p <0.05 at 24 hrs., and
MS uptake was significantly lower with p <0.05 (Figure 23).
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Figure 22 Biodistribution of BMDM Loaded with DOPC-DOPS Protocells. BMDM
were co-incubated with DOPC-DOPS protocells labeled with Indium-111 and Dylight 650
and adoptively transferred into FVB mice. SPECT/CT images suggest that protocell
distribution is localized to the lungs within 30 min. of injection. The sample migrates to
the liver, kidneys and spleen over 24 hrs. The protocells loaded BMDMs do not
accumulate in the normal mammary tissue of FVB mice.
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The quantified mammary ROI uptake suggests a marked increase in tumor
uptake after 24 hrs. in both MS-mediated and directly injected DOPC-DOPS
protocells (Figure 23C). In all cases, the majority of protocells ended up in the
liver and kidneys (Figure 24-26). The quantified mammary ROI signal suggests
a significant accumulation in the lungs after 30 min. circulation by BMDM
mediated delivery compared to the other cohorts (Figure 27). Protocells
accumulated in the bones of FVB mice more significantly than in PyMT mice
(Figure 27). All cohorts demonstrated initial uptake by the heart that decreased
over time. The BMDM at 30 min. post injection showed the highest heart uptake
of all cohorts (Figure 29).
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Figure 23: SPECT/CT Analysis of Protocell Delivery to Tumor/Mammary Tissue.
MS loaded or direct DOPC-DOPS protocells labeled with Indium-111 and Dylight 650
were injected into PyMT and FVB mice. The percent injected dose per gram of tissue
(%ID/g) was determined from tumor ROIs and two-way analysis of variance (ANOVA) of
each group was carried out analyzed by time and injectate. MS-mediated protocell
delivery improved significantly over time (A) and showed slightly higher tumor uptake
compared to directly injected protocells, but the difference was not significant (C). Both
directly injected and MS-mediated protocell delivery is enhanced in tumors compared to
normal mammary tissue (A & B). There was significantly less effective protocell delivery
to mammary tissue in FVB mice mediated by BMDM compared to MS-mediated or
directly injected protocells (D).
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Figure 24: SPECT/CT Analysis of Protocell Delivery: Tumor-to-Liver Ratio. MS
loaded or direct DOPC-DOPS protocells labeled with Indium-111 and Dylight 650 were
injected into PyMT and FVB mice. The tumor-to-liver ratio was computed, and two-way
ANOVAs of each group analyzed by time and tumor to organ ratio per injectate. The
tumor-to-liver ratio achieved using MS-mediated protocell delivery to tumor versus liver
was higher in PyMT mice compared to FVB at all time points (A). MS delivery resulted
in an increasing tumor-to-liver ratio as a function of time in PyMT mice, although the
trend was not matched in FVB mice (B). Direct injection of protocells resulted in similar
tumor-to-liver ratios at 30 min. and 5 hrs. when comparing PyMT and FVB mice.
However, at 24 hrs. the tumor-to- liver ratio was significantly higher in PyMT mice (B).
MS-mediated delivery was significantly higher than direct injection at 24 hrs (C).

66

Figure 25: SPECT/CT Analysis of Protocell Delivery: Tumor-to-Kidney Ratios.
DOPC-DOPS protocells labeled with Indium-111 and Dylight 650 were loaded into MS
for adoptive transfer or directly injected into PyMT and FVB mice. The tumor-to-kidney
ratio was computed and we performed two-way ANOVAs of each group analyzed by
time and tumor to organ ratios per injectate. The tumor-to-kidney ratio optained after
MS-mediated tumor delivery was higher in PyMT mice compared to FVB with statistical
significance achieved at 5 hrs circulation (A). Directly injected protocells also resulted in
a higher tumor-to-kidney ratio in PyMT mice (for both MS-mediated delivery and direct
injection), but this trend was not observed in FVB mice (B). MS-mediated protocell
delivery did not result in a statistically significant difference in the tumor-to-kidney ratio
when compared to direct injection (C).
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Figure 26: SPECT/CT Analysis of Protocell Delivery to Spleen. Indium-111 and
Dylight 650 labeled DOPC-DOPS protocells were loaded into MS for adoptive transfer or
direct injection into PyMT and FVB mice. The tumor-to-spleen ratio was determined at
each time point and two-way ANOVAs of each group were performed by time and
injectate. With respect to the tumor-to-spleen ratio, MS-mediated tumor delivery was
slightly better in PyMT mice compared to FVB (A), but the difference was not significant.
Directly injected protocells resulted in a higher mammary-to-spleen ratio in FVB mice
relative to PyMT mice after 30 min. circulation (B). The tumor-to-spleen ratios achieved
by MS-mediated protocell delivery are generally superior to direct injection, but the
difference is not statistically significant (C).
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Figure 27: SPECT/CT Analysis of Protocell Delivery to Lungs. DOPC-DOPS
protocell labeled with Indium-111 and Dylight 650 were loaded into MS for adoptive
transfer or direct injection into PyMT and FVB mice. ROIs of the lung were analyzed
and two-way ANOVAs of each group analyzed by time and injectate. MS-mediated
protocell delivery to the lungs is not significantly different from directly injected protocells
(A). However, BMDM delivered protocells accumulated more significantly in the lungs of
FVB mice after 30 min. circulation in comparison to both MS-mediated delivery and
direct injection of protocells.(B). Both MS-mediated delivery and direct injection of
protocells resulted in delivery to lung that was not significantly different in PyMT mice
compared to FVB (C & D). Both MS-mediated and direct protocell delivery to the lungs
are not significantly different between genotypes (C&D).
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Figure 28: SPECT/CT Analysis of Protocell Delivery to Bones. DOPC-DOPS
protocell labeled with Indium-111 and Dylight 650 were loaded into MS for adoptive
transfer or direct injection into PyMT and FVB mice. ROIs of the lung were analyzed
and two-way ANOVAs of each group analyzed by time and injectate. MS-mediated
protocell delivery resulted in higher bone uptake relative to direct injection in PyMT mice,
but the difference was not significant (A). Both MS-mediated and directly injected
protocells accumulated more significantly in the bones of FVB mice compared to BMDM
delivery at 30 min (B). Both MS-mediated and direct protocell delivery to the bones is
significantly different between genotypes with FVB mice showing significantly higher
bone uptake (C & D).
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Figure 29: SPECT/CT Analysis of Protocell Delivery to Heart. DOPC-DOPS
protocell labeled with Indium-111 and Dylight 650 were loaded into MS for adoptive
transfer or direct injection into PyMT and FVB mice. ROIs of the lung were analyzed
and two-way ANOVAs of each group analyzed by time and injectate. MS-mediated
protocell delivery was significantly higher in PyMT mice compared to FVB after 30 min.
circulation (A) and the signal declined over 24 hrs. Direct protocell delivery to the heart
is not significantly different between genotypes and the signal declines over 24 hrs (B).
MS-mediated protocell delivery to the heart was significantly higher than direct protocell
delivery at 30 min. and 5 hrs. circulation (C).
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Chapter 6
Discussion
6.1 INTRODUCTION
Nanotherapeutics are substantially contributing to cancer therapies and
emerging as powerful treatment modalities for breast cancer. Some of the
common issues concerning conventional chemotherapeutics, such as limitations
in achievable doses within the tumor and cancer cell resistance to molecularly
targeted chemotherapeutics, are mitigated by nanomaterials. Targeted
nanoparticles, for example, enter cancer cells by receptor mediated endocytosis
rather than passive diffusion through the cell membrane, thus avoiding Pglycoprotein recognition and subsequent efflux back out of the cell (Larsen
2000). The versatility and biocompatible properties of nanotechnology combined
with advancements in our understanding of tumor growth and invasion has
allowed for a rapid expansion of the field of nanomedicine with copious
developments of new nanoparticles for the diagnosis and treatment of cancer.
Polymeric micelles, for example, resolve the issue of solubilizing typically
hydrophobic chemotherapeutics in biocompatible aqueous media. These water
soluble amphiphilic block copolymers assemble into nanoshells with a
hydrophobic core region which stabilizes the hydrophobic drug, rendering the
drug water-soluble and allowing for IV administration (Adams 2003). A polymeric
micelle formulation of Paclitaxel demonstrates current clinical application of this
technology, as it is commonly used to treat patients with advanced refractory
malignancies (Kim 2004).
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Investigations into chemotherapeutic transport phenomena are inspiring
researchers to reassess nanoscale drug carrier designs to overcome biological
barriers while enhancing drug accumulation within tumors and incorporating
controlled release mechanisms for depositing drug payloads. Liposomes are a
popular design effort to meet the goals of drug encapsulation, targeting, and
release. Liposomes are self-assembling colloidal structures of lipid bilayers that
can be modified with targeting ligands and different lipid compositions to improve
targeting while protecting the drug en route. This technology is successfully
used in cancer therapy with Doxorubicin and Anthracylines, which are commonly
used for treating metastatic breast cancer (Rivera 2003; Markman 2006).
Protocells are another class of nanocarrier that modifies liposome technology
with mesoporous silica particles to provide a versatile platform for addressing the
multiple challenges of targeted delivery. The mesoporous silica core provides a
high surface area that enables a higher drug loading capacity than is afforded in
traditional liposomes of similar size. Doxorubicin loading of protocells showed a
1,000-fold increase in loading capacity compared to similarly sized liposomes
(Ashley 2011). The charged silica core stabilizes the phospholipid bilayer
resulting in greater stability and increased bilayer fluidity, which improves the
efficiency and targeting specificity of targeting ligands at a minimal ligand
concentration (Ashley 2011). Protocells also incorporate a pH dependent
release mechanism whereby low pH destabilizes the phospholipid bilayer,
allowing the encapsulated drug to be released.
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Combining multimodal delivery platforms with a means of active delivery will
significantly enhance the performance of drug carriers in cancer therapeutics.
Advancements in immunotherapy and tumor immunology have elucidated a
heterogeneous population of circulating mononuclear cells that play a significant
role in tumor inflammation and infection (Wynn 2013). Mononuclear phagocytes
in particular are extensively recruited during inflammation and are known to
accumulate in hypoxic regions of tumors, including breast carcinomas, due to the
cytokines released by tumor cells in response to hypoxia (Leek 1996). This is an
advantage for using mononuclear phagocytes to distribute cancer therapeutics
throughout the interior of the tumor because hypoxia is typically widespread in
malignant tumors due to the disorganized vascular architecture and poor
lymphatic drainage (Batrakova 2011; Kobayashi 2014). Therefore, we
hypothesized that circulating mononuclear cells are effective biologically active
carriers of cancer nanotherapeutics and investigated merging immunotherapy
with targeted drug delivery of protocell multimodal nanotherapeutic platforms.

6.2 DISCUSSION OF RESULTS AND CONCLUSIONS
Mononuclear cells were isolated from the spleen, a known reservoir of
mononuclear cell that expands in cancer (Cortez-Retamozoa 2012). Our results
demonstrate isolation of viable MS (Figure 1) that do not have uniform nuclear
morphology, a morphological feature of mature macrophages, and the nucleus to
cytoplasm ratio is much larger than is typically seen in mature macrophages
(Figures 1 and 2). A significant proportion of MS express Ly6C/G (Gr1) (Figure
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3), which is indicative of inflammatory monocytes, a heterogeneous population
that lacks classic features of mature macrophages and dendritic cells and is
known to expand in during cancer inflammation and infection (Wynn 2013).
TAMs are also prominently featured in many inflammatory responses to tumors
and commonly express F4/80 and CD11b, so we investigated the efficacy of MSmediated drug delivery in comparison with BMDM (Balkwilla 2012). BMDM were
shown to be strongly F4/80 and CD11b positive, as shown in Figure 3,
suggesting a mature macrophage phenotype (Hume 2002). Both MS and
BMDM are phagocytic (Figures 4 and 5), demonstrating the capacity to take up
particulates on order of the typical size of nanotherapeutics (Cheng 2012). MS
and BMDM tumor targeting in vivo was assessed by adoptive transfer into tumor
bearing PyMT mice and compared against FVB mice with normal mammary
tissue. SPECT/CT analysis of IV injected MS suggests about a three-fold larger
proportion of MS migrate to tumor tissue versus normal mammary tissue (Figure
6-8), which is suggestive of a prevalent inflammatory responsive subset of the
MS population. Alternatively, BMDM directly migrate to the lungs initially,
followed by a gradual migration into common filtering organs, such as the liver,
kidneys, and spleen (Figure 10). There was no detectable signal of adoptively
transferred MS in the lungs, which is suggestive of a primarily immature
mononuclear population of mononcytes rather than differentiated macrophages
(Figure 6-8). Further characterization of BMDM is required to elucidate why
there is such a specific migration to the lungs and not an affinity for the tumors.
Typically circulating macrophages are thought to migrate to tumors (Movahedi
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2010), so further immunological staining for other cell surface markers, such as
MHC classes 1 and 2 receptors, might indicate why BMDM do not migrate to
tumors.
A more intriguing aspect of MS biodistribution observed in vivo is that MS
infiltration into tumor tissue is impacted by the duration of incubation at 37°C
prior to adoptive transfer. Tumor targeting appeared to be enhanced the longer
the injectate incubated at 37°C, however cytokine array analysis revealed no
detectable activation state of the injectate population prior to adoptive transfer
(Figure 11). There appeared to be no significant change in cell surface
expression markers, but there was a slight increase in phagocytic behavior, as
observed through flow cytometric quantification of PKH26 micelle uptake (Figure
12). Several subtle differences in MS population dynamics were observed in the
size and granularity of cells, as seen by flow cytometry. The lymphocyte and
monocyte populations diverged into two subsets. The lymphocytes were smaller
in size and the monocytes were less granular (Figure 13). A third population of
small size and high granularity appears after four hours incubation at 37°C,
which suggests a possible differentiation of myeloid cells into tumor suppressor
cells that are highly granular. These are perhaps polymorphonuclear myeloid
derived suppressor cells, which are consistently the dominant population of
expanding mononuclear cells in tumor-bearing hosts (Wynn 2013). Further
characterization of the cell population as a function of time incubated at 37°C is
required to elucidate the link between sample preparation and in vivo
biodistribution.
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In order to determine whether MDSC were the subset of the MS population
that targeted the tumors, we attempted to purify Ly6C (Gr1)/CD11b positive cells
using mouse monocyte enrichment kits (StemCell). We demonstrate enrichment
of CD11b+ MS by negative selection and further enrichment of Ly6C (Gr1)
positive cells through a positive selection kit, however the yield decreased by an
order of magnitude, which proved this method impractical for MDSC isolation
from the spleen (Figure 15). Therefore, we investigated the tumor affinity of the
phagocytic subset of MS as possible nanotherapeutic carriers. MS were labeled
with PKH26 fluorescent micelles and tracked in vivo post adoptive transfer into
PyMT mice. The majority of the MS population took up PKH26 micelles, the bulk
of which were phagocytosed by cells exhibiting macrophage forward and side
scatter characteristics (Figure 4). This large percentage of phagocytic MS
reflects previous studies estimating up to 8% of the mononuclear fraction of
blood obtained from patients with lymphoctyic leukemia to be phagocytic
(Zucker-Franklin 1974).
To confirm that MS can carry cargo to tumors in vivo, we adoptively
transferred PKH26 loaded MS into PyMT mice. Upon cryosectioning the tumors,
we observed delivery of PKH26 loaded MS to tumors (Figure 14). There
appears to be an association with pockets of little to no DAPI nuclear staining
and very highly disorganized WGA. WGA is an agglutinin protein, or lectin, that
binds to N-acetyl-D-glucosamine and Sialic acid. Metastatic cancer cells are
known to express a high density of sialic acid-rich glycoproteins (Narayanan
1994). Also, WGA has been shown to recognize lectin groups significantly more
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prevalently in hypoxic lesions found in DCIS than in non-hypoxic regions and the
staining is primarily cytoplasmic (Barreto de Melo Rêgo 2013). MS are known to
have an affinity for hypoxic regions of tumors, so it is possible that MS target
hypoxic lesions of the tumor (Movahedi 2010). However, further investigation is
required in order to make any strong conclusions regarding this phenomenon.
For example, histological staining of sialic acid and glycoproteins would confirm
whether the low DAPI regions observed are associated with an increase in sialic
acid and glycoprotein secretion or cell surface expression compared to normal
mammary tissue. The lack of DAPI stained nuclei observed in these high WGA
stained regions combined with the aggregated morphology of WGA staining
possibly suggests WGA staining mucin glycoprotein, which are heavily secreted
in metastatic tumors and are often localized to luminal regions that have low cell
density. High mucin secretion is thought to provoke immune responses in
patients with carcinomas, which might MS association with these regions of the
tumor (Varki 2009).
Having established MS tumor targeting in vivo post adoptive transfer, we next
investigated the capacity of MS to transport cargo to tumors in vivo. We chose
to incorporate protocells as a mock cargo because they are actively being
pursued as a multicomponent targeted nanotherapeutic (Ashley 2011). We
demonstrate the capacity of MS to uptake protocells of different lipid
compositions (Figure 16, Tables 1-3 in appendix). Lipid formulation directly
impacted MS viability and protocell uptake. Charged nanoparticles, for example,
are known to rapidly be taken up by monouclear phagocytes more readily
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compared to neutral particles (Juliano 1975; Lee 1992). Positively charged
particles are phagocytosed by mononuclear phagocytes to a greater extent than
negatively charged particles, as was seen in retroviral uptake studies comparing
mononuclear phagocyte uptake of positively versus negatively charged
nanoparticles that were homogenized with antiretroviaral drugs. Mononuclear
cell uptake of positively charged nanoparticles was two-fold higher than with
negatively charged particles (Nowacek 2009). Therefore, positively charged
DOPC-DOPS protocells were compared against negatively charged DOPCDOTAP protocells. DOPC-DOPS protocells were readily taken up by MS and did
not significantly impact cell viability at low concentrations, on the order of 125
ug/mL (Figure 16). DOPC-DOTAP, negatively charged, particles were cytotoxic
at high concentrations, though particle uptake was enhanced (Figure 16). These
results demonstrate that MS can be loaded with a variety of particle formulations,
but are most compatible with DOPC-DOPS protocells after incubation for 1 hr at
37⁰C.
PEG coated nanocarriers are one of the most common particles used for
injectable nanotherapeutics because PEG is electrostatically neutral and
hydrophilic, which protects the nanocarrier from immune recognition (Katrin Knop
2010). Several PEG carriers have been approved for clinical treatment of
metastatic breast cancer (Papaldo 2006). However, PEG particles are likely not
compatible with cell mediated therapeutics, as PEG tends to limit cellular uptake
(Gbadamosi 2002). Therefore, PEG coated DOPS protocells were compared
with DOPC-DOPS and DOPC-DOTAP protocells to assess the efficacy of
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evading the immune response extracellularly by PEG or intracellularly by
immune cell drug delivery. PEG coated particles did not severely impact cell
viability, but particle uptake was less efficient compared to other formulations
(Figure 16). These findings support other studies that suggest nanoparticles with
PEG coronas are stable and have limited cytotoxicity, but are less readily taken
up by mononuclear phagocytes compared to particles without a PEG corona
(Batrakova 2011).
The efficacy of MS or BMDM transport of protocells compared to direct
injection was assessed in vivo by SPECT/CT. The quantified mammary ROIs of
the brain, liver, kidneys, bone, heart, spleen, and tumors/mammary glands
demonstrate comparable tumor delivery of protocells with MS, compared to
directly injected protocells, and not in BMDM (Figure 24), suggesting an
immature immune cell phenotype is more desirable for drug transport. The
similar performance between direct IV delivery of protocells versus MS-mediated
delivery suggest the diffusion properties of charged protocells is on the order of
MS recruitment to tumors. However the similar aggregation patterns of both
direct and MS-mediated protocells observed in the tumor sections are suggest
the protocells are being readily taken up by circulating and/or tissue resident
phagocytic cells (Figures 18 & 24). Also, analysis of the tumor to organ ratios of
MS-mediated protocell delivery are generally not significantly higher than directly
injected protocells. DOPC-DOPS protocells are positively charged, which
stimulates uptake by endogenous phagocytic immune cells and might account
for the comparability of directly injected protocells with immune cell mediated
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protocell delivery. Further hystological staining for possible tissue resident
phagocytic cells is required to confirm the association of directly injected
protocells with phagocytic cells in the tumors.
BMDM are potentially viable candidates for lung therapeutics, which further
validates efforts towards harnessing immune cells for targeted therapies. Both
interstitial macrophages and lung associated dendritic cells are F4/80 and
CD11b double positive, so perhaps the almost immediate association of BMDM
with the lungs post adoptive transfer indicates BMDM are more closely
differentiated towards the phagocytic cell types typically associated with the lung.
This study demonstrates a potential for immune cell mediated targeted drug
delivery that is applicable to the clinic because cell carriers can be harvested
from peripheral blood, loaded with particles and re-injected into the patient.
Another advantage to utilizing mononuclear cells is that they may be alternatively
harvested from bone marrow, which has the advantage of differentiating
particular cell types form hematopoetic stem cells and propagating them in
culture to obtain higher concentrations of cells that can be adoptively transferred
back into the patient once loaded with drug cargo. The directly injected protocell
experiments from this study suggest that a third clinical application is potentially
available, where the particles are formulated to be taken up by circulating cell
carriers in the patient upon IV injection of the particles. Targeting of circulating
cells can be achieved by attaching receptor ligands such as folate, fibronectin,
mannose or RGD peptide to the particles, which are recognized my mononuclear
phagocytes (Batrakova 2011).
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6.3 RECOMMENDATIONS FOR FURTHER RESEARCH
Further investigation into MS-mediated therapeutic delivery is required to fully
understand the potential. A more efficient purification method, such as FACS
sorting, might improve optimization of biodistribution among MS. The
interestingly significant improvement in tumor to organ signal observed in the
MS-mediated protocell delivery of the PyMT mouse that was not properly
injected suggests that immune cell targeting of the tumor might be improved by
alternative injection routs, such as intramuscular, peritoneal, or subcutaneous.
Investigation into drug release mechanisms should occur in conjunction with
optimizing the immune cell carrier population in order to develop a biologically
compatible and controllable multimodal platform for immune based targeted
therapies with an ultimate goal of testing the efficacy of cell-mediated delivery of
drug-loaded protocells on tumor progression. The dynamic vesicle system of
mononuclear phagocytes could be exploited as a potential release mechanism
for nanotherapeutics because mononuclear phagocytes are known to both
generate and store different compounds in intracellular vesicles that are
exocytosed at the site of infection (Batrakova 2011). Another option is to elicit
an intracellular timed relaese of calcium in order to induce the immune cell
carrier into apoptosis and ultimate release of the cargo (Söllner 1993). This
study supports the concept that success in utilizing innate and adaptive immune
mechanisms to assist with drug delivery will change our perspective towards
clinical treatment strategies.
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Appendix
Time Incubated
20 min

1 hr

2 hrs

Time Incubated
20 min

1 hr

2 hrs

Time Incubated
20 min

1 hr

2 hrs

[Protocell] (ug/mL)
1000
500
250
125
50
1
0.5
1000
500
250
125
50
1
0.5
1000
500
250
125
50
1
0.5

%Live
46.1
8.39
8.45
23.6
24.9
90.4
80.6
28.5
50.9
63.6
67.5
65.4
70.4
89
50.5
52
82.2
92
98
95.3
96.3

% Dead
53.9
91.6
91.6
76.4
75.1
9.55
19.4
71.4
49.1
36.4
32.5
34.6
29.6
11
4.68
48
17.8
8.05
2.03
4.68
3.68

% DOPC-PEG PC Uptake (live)
65.2
70.3
61.4
69.9
65.8
15.4
12.9
65.5
53.8
48.4
40.3
35.8
3.22
1.59
82.6
69.2
46.8
43.9
34.7
4.15
3.17

[Protocell] (ug/mL)
1000
500
250
125
50
1
0.5
1000
500
250
125
50
1
0.5
1000
500
250
125
50
1
0.5

%Live
9.68
25
35.9
55
47.3
79.3
91.5
8.33
5.55
18
47.7
53.1
95
92.6
3.9
4.08
15.9
46.4
49.5
92.4
94

% Dead
90.3
75
64.1
45
52.7
20.7
8.46
91.7
94.4
82
52.3
46.9
5.04
7.42
7.58
95.9
84.1
53.6
50.5
7.58
6

% DOPC-DOTAP PC Uptake (live)
70.7
73.7
70.8
60.5
60.5
31.3
7.61
97.9
75.9
74
89.1
89.7
34.6
22.2
97.1
65.5
69.5
75.5
78.8
26.5
16.6

[Protocell] (ug/mL)
1000
500
250
125
50
1
0.5
1000
500
250
125
50
1
0.5
1000
500
250
125
50
1
0.5

%Live
2.23
49
49.7
79.1
31.8
85.6
83.6
86.9
85
65.5
85.8
93.4
92.6
93.1
70.4
60
56.8
64.5
95.1
84.6
81.7

% Dead
97.8
51
50.3
20.9
68.2
14.4
16.4
13.1
15
34.5
14.2
6.65
7.44
6.88
15.4
40
43.2
35.5
4.89
15.4
18.3

% DOPC-DOPS PC Uptake (live)
97.3
63.7
47.2
44.6
23.9
29.5
17.2
96.3
93.3
82.1
77.6
68.7
15.5
11
96.8
92.9
85.1
72.3
68.1
10.7
13.2
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